Prevalence of malignant tumors among residents in Shaanxi province, 2019: a hospitalization records-based analysis
-
摘要:
目的 了解陕西省居民2019年恶性肿瘤患病情况，为陕西省恶性肿瘤防治工作提供参考依据。 方法 收集陕西省2019年1月1日 — 12月31日住院病案首页中恶性肿瘤患者相关数据，根据国际疾病分类第10次修订版（ICD-10）划分住院患者的恶性肿瘤类别，并采用多重插补法调整住院患者缺失的协变量条目，根据全国年龄别人口数标化恶性肿瘤的年龄别患病率。 结果 陕西省居民2019年恶性肿瘤患病率为392.38/10万，其中铜川市居民的恶性肿瘤患病率最高（523.68/10万），渭南市居民的恶性肿瘤患病率最低（342.56/10万）；消化器官恶性肿瘤为2019年陕西省居民罹患的主要恶性肿瘤，患病率为144.21/10万；男性居民患病率居于前3位的恶性肿瘤分别为消化器官恶性肿瘤（187.50/10万）、呼吸和胸腔内器官恶性肿瘤（106.25/10万）和淋巴、造血和有关组织的恶性肿瘤或假定为原发性的恶性肿瘤（31.05/10万），女性居民患病率居于前3位的恶性肿瘤分别为消化器官恶性肿瘤（98.04/10万）、乳房恶性肿瘤（70.60/10万）和女性生殖器官恶性肿瘤（67.18/10万），城市居民患病率居于前3位的恶性肿瘤分别为消化器官恶性肿瘤（109.72/10万）、呼吸和胸腔内器官恶性肿瘤（58.15/10万）和乳房恶性肿瘤（30.13/10万），农村居民患病率居于前3位的恶性肿瘤分别为消化器官恶性肿瘤（194.32/10万）、呼吸和胸腔内器官恶性肿瘤（100.14/10万）和女性生殖器官恶性肿瘤（45.37/10万）；不同年龄段居民恶性肿瘤患病类别不同，其中65～69岁居民的年龄别标化恶性肿瘤患病率最高（62.89/10万）。 结论 2019年陕西省铜川市居民恶性肿瘤患病率较高，消化器官恶性肿瘤为危害陕西省居民健康的主要恶性肿瘤，不同性别、年龄和居住地居民恶性肿瘤患病情况不同，应针对不同特征居民开展相应的肿瘤早期筛查工作控制肿瘤的流行。 Abstract:Objective To examine the prevalence of malignant tumors among residents in Shaanxi province in 2019. Methods All hospitalizations due to malignant tumors throughout 2019 were extracted from inpatient medical records of hospitals in Shaanxi povince. The International Classification of Diseases, 10th Revision (ICD-10) was used to categorize the inpatients′ malignant tumors and multiple imputation method was adopted to adjust the covariates with missing data. National and provincial demographics were collected from National Bureau of Statistics and Statistics Yearbook of Shaanxi province for calculating age-adjusted prevalence rate. Results The overall prevalence rate (1/100 000) of malignant tumors in the province during 2019 was 392.38; the highest regional prevalence rate was 523.68 for the residents of Tongchuan prefecture, while the lowest was 34.256 for those of Weinan prefecture; and the highest tumor-specific prevalence rate was 144.21 for digestive malignancies. In the male residents of the province, the top three prevalence rates were 187.50, 106.25, and 31.05 for malignancies of digestive organs, respiratory and intrathoracic organs, and lymphoid, hematopoietic and related tissues; in the female residents, the top three prevalence rates were 98.04, 70.60, and 67.18 for malignancies of digestive organs, breast, and female reproductive organs; the top three prevalence rates were 109.72, 58.15, and 30.13 for malignancies of digestive organs, respiratory and intrathoracic organs, and breast in the urban residents of the province, but in the rural residents, the top three prevalence rates were 194.32, 100.14, and 45.37 for malignancies of digestive organs, respiratory and intrathoracic organs, and female reproductive organs, respectively. The prevalent malignancies differed among the residents of various age groups and the age-specific prevalence rate of malignancies was the highest (62.89) for the residents aged 65 – 69 years. Conclusion Among the residents in Shaanxi province during 2019, the overall prevalence rate of malignancies was relatively high and malignant tumor of digestive organs was the most prevalent malignancy; the prevalence rates of malignancies differed among the residents of different gender, various ages, and living in different regions; the results need to be concerned in early screening and control of malignant tumors in the province. -
Key words:
- malignant tumor /
- prevalence /
- early screening
-
表 1 陕西省2019年不同特征居民恶性肿瘤患病情况比较
Table 1. Gender-, age-, and living region-specific prevalence of malignant tumor among residents of Shaanxi province, 2019: hospitalization records-based analysis
特征 患病数（例） 患病率（1/10万） χ2 值 P 值 性别 男性 82907 414.76 529.67 < 0.001 女性 69057 368.50 年龄（岁） 0 71 17.36 207675.45 < 0.001 1～4 427 32.59 5～9 564 29.32 10～14 342 21.41 15～19 339 21.38 20～24 473 22.90 25～29 1336 40.58 30～34 2506 61.48 35～39 3693 124.35 40～44 5433 206.36 45～49 11129 330.65 50～54 15236 477.19 55～59 19057 696.04 60～64 22141 965.29 65～69 23833 1246.51 70～74 18611 1467.56 75～79 14260 1538.60 80～84 8454 1342.30 ≥ 85 4059 751.87 城乡 城市 71346 311.00 9533.40 < 0.001 农村 80618 510.61 
下载: 导出CSV
表 2 陕西省2019年不同性别和城乡居民各类恶性肿瘤患病情况
Table 2. Prevalence of major malignant tumors by gender and living region among residents of, Shaanxi province, 2019: hospitalization records-based analysis
恶性肿瘤类别 性别 城乡 男性 女性 城市 农村 患病数（例） 患病率
（1/10万）患病数（例） 患病率
（1/10万）患病数（例） 患病率
（1/10万）患病数（例） 患病率
（1/10万）唇、口腔和咽恶性肿瘤 1309 6.55 600 3.20 846 3.69 1063 6.73 消化器官恶性肿瘤 37479 187.50 18372 98.04 25170 109.72 30681 194.32 呼吸和胸腔内器官恶性肿瘤 21238 106.25 7912 42.22 13340 58.15 15810 100.14 骨和关节软骨恶性肿瘤 310 1.55 246 1.31 228 0.99 328 2.08 皮肤黑色素瘤和其他恶性肿瘤 600 3.45 575 3.07 559 2.44 706 4.47 间皮组织和软组织恶性肿瘤 445 2.23 415 2.21 416 1.81 444 2.81 乳房恶性肿瘤 110 0.55 13230 70.60 6911 30.13 6429 40.72 女性生殖器官恶性肿瘤 0 0 12590 67.18 5426 23.65 7164 45.37 男性生殖器官恶性肿瘤 3509 17.55 0 0 1954 8.48 1564 9.91 泌尿道恶性肿瘤 4207 21.05 1694 9.04 3050 13.30 2851 18.06 眼、脑和中枢神经系统其他部位的恶性肿瘤 854 4.27 649 3.46 709 3.09 794 5.03 甲状腺和其他内分泌腺恶性肿瘤 1439 7.20 3777 20.15 2846 12.41 2370 15.01 不明确、继发和未特指部位的恶性肿瘤 5049 25.26 4173 22.27 4572 19.93 4650 29.45 淋巴、造血和有关组织的恶性肿瘤或假定为原发性的恶性肿瘤 6206 31.05 4783 25.52 5279 23.01 5710 36.17 独立（原发）多个部位的恶性肿瘤 62 0.31 41 0.22 49 0.21 54 0.34
下载: 导出CSV
表 3 陕西省居民2019年年龄别恶性肿瘤标化患病率（1/10万）
Table 3. Age-specific prevalence of major malignant tumors among residents of Shaanxi province, 2019: hospitalization records-based analysis
恶性肿瘤类别 年龄（岁） 0 1～4 5～9 10～14 15～19 20～24 25～29 30～34 35～39 40～44 45～49 50～54 55～59 60～64 65～69 70～74 75～79 80～84 ≥ 85 唇、口腔和咽恶性肿瘤 0 0 0.01 0.02 0.01 0.01 0.05 0.08 0.12 0.25 0.43 0.55 0.70 0.63 0.78 0.50 0.32 0.20 0.08 消化器官恶性肿瘤 0.04 0.09 0.02 0.01 0.04 0.13 0.33 0.87 1.80 3.45 7.24 12.50 16.70 20.86 26.02 21.05 14.59 8.17 3.03 呼吸和胸腔内器官恶性肿瘤 0.02 0.02 0.02 0.01 0.02 0.01 0.11 0.24 0.51 0.98 3.06 5.71 8.74 12.29 15.23 12.18 7.50 3.73 1.34 骨和关节软骨恶性肿瘤 0 0.01 0.06 0.10 0.05 0.06 0.03 0.05 0.04 0.05 0.11 0.11 0.17 0.13 0.16 0.15 0.08 0.05 0.01 皮肤黑色素瘤和其他恶性肿瘤 0 0 0 0 0 0.02 0.02 0.02 0.07 0.08 0.22 0.30 0.34 0.34 0.46 0.40 0.34 0.24 0.17 间皮组织和软组织恶性肿瘤 0.01 0.08 0.03 0.02 0.02 0.03 0.03 0.05 0.08 0.09 0.18 0.24 0.23 0.26 0.31 0.21 0.17 0.12 0.01 乳房恶性肿瘤 0 0 0 0 0.01 0.04 0.28 1.01 2.01 3.44 6.20 6.11 4.70 4.03 3.26 1.49 0.65 0.40 0.11 女性生殖器官恶性肿瘤 0 0.01 0 0.04 0.03 0.13 0.38 0.69 1.22 2.32 4.51 5.81 5.33 4.35 3.60 1.95 0.93 0.40 0.10 男性生殖器官恶性肿瘤 0.02 0.03 0.01 0 0.01 0.02 0.04 0.05 0.11 0.07 0.10 0.22 0.45 0.80 1.37 1.73 1.54 1.10 0.53 泌尿道恶性肿瘤 0.02 0.06 0.05 0.01 0 0.01 0.07 0.10 0.18 0.32 0.75 1.24 1.41 1.95 2.56 2.18 1.74 1.09 0.54 眼、脑和中枢神经系统其他部位的恶性肿瘤 0.01 0.11 0.09 0.09 0.05 0.06 0.13 0.14 0.16 0.25 0.47 0.44 0.47 0.46 0.41 0.25 0.13 0.09 0.02 甲状腺和其他内分泌腺恶性肿瘤 0.01 0.02 0.01 0.02 0.06 0.28 0.79 1.01 1.23 1.63 2.29 2.12 1.66 0.84 0.61 0.31 0.13 0.05 0.01 不明确、继发和未特指部位的恶性肿瘤 0.02 0.04 0.02 0.04 0.06 0.06 0.18 0.29 0.45 0.68 1.58 2.52 3.15 3.35 4.04 2.85 1.91 1.12 0.41 淋巴、造血和有关组织的恶性肿瘤或
假定为原发性的恶性肿瘤0.04 1.07 1.32 0.81 0.73 0.43 0.60 0.68 0.87 0.96 1.79 2.79 3.15 3.32 4.04 2.65 1.82 0.84 0.25 独立（原发）多个部位的恶性肿瘤 0 0 0 0 0 0 0 0 0 0 0.02 0.03 0.01 0.04 0.04 0.04 0.04 0.01 0.01
下载: 导出CSV
-
[1] Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019[J]. JAMA Oncology, 2022, 8(3): 420 – 444. doi: 10.1001/jamaoncol.2021.6987 [2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660 [3] 国家统计局. 中国统计年鉴2021[M]. 北京: 中国统计出版社, 2021. [4] 文小焱, 潘惊萍, 段占祺, 等. 2013 — 2017年四川省居民恶性肿瘤疾病负担研究[J]. 中国肿瘤, 2020, 29(10): 758 – 762. [5] 刘劲松, 王华东, 张新洲, 等. 2015年安徽省恶性肿瘤疾病负担分析[J]. 中华疾病控制杂志, 2022, 26(3): 362 – 366. [6] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990 – 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. The Lancet, 2020, 396(10258): 1204 – 1222. doi: 10.1016/S0140-6736(20)30925-9 [7] Sun DQ, Li H, Cao MM, et al. Cancer burden in China: trends, risk factors and prevention[J]. Cancer Biology and Medicine, 2020, 17(4): 879 – 895. doi: 10.20892/j.issn.2095-3941.2020.0387 [8] World Health Organization. International statistical classification of diseases and related health problems[M]. 5th ed. Geneva: World Health Organization, 2015. [9] 陕西省统计局, 国家统计局陕西调查总队. 陕西统计年鉴2020[M]. 北京: 中国统计出版社, 2020. [10] 郭佳, 贺媛, 王学梅, 等. 中国居民1990年与2017年胃癌疾病负担比较[J]. 中国公共卫生, 2022, 38(5): 547 – 552. [11] 路友华, 王炳翔, 王家林, 等. 中国居民1990 — 2019年肺癌及其危险因素疾病负担变化趋势分析[J]. 中国公共卫生, 2022, 38(5): 513 – 517. [12] 崔芳芳, 鲍俊哲, 王琳琳, 等. 1990 — 2019年中国女性“两癌”疾病负担变化趋势及预测分析[J]. 中国卫生统计, 2022, 39(5): 647 – 652. [13] Qiu HB, Cao SM, Xu RH. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Communications, 2021, 41(10): 1037 – 1048. doi: 10.1002/cac2.12197 [14] Zong L, Abe M, Seto Y, et al. The challenge of screening for early gastric cancer in China[J]. The Lancet, 2016, 388(10060): 2606. doi: 10.1016/S0140-6736(16)32226-7 [15] Yang L, Kartsonaki C, Yao P, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study[J]. The Lancet Public Health, 2021, 6(12): e888 – e896. doi: 10.1016/S2468-2667(21)00164-X [16] 国家卫生健康委员会. 2021中国卫生健康统计年鉴[M]. 北京: 中国协和医科大学出版社, 2021. [17] Graham DY, Dang BN, El-Serag HB. Helicobacter pylori infection[J]. New England Journal of Medicine, 2019, 381(6): 587 – 588. doi: 10.1056/NEJMc1905439 [18] World Health Organization. Hepatitis[EB/OL]. (2020 – 11 – 10)[2022 – 10 – 15]. https://www.who.int/health-topics/hepatitis#tab=tab_1. [19] De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. The Lancet Oncology, 2010, 11(11): 1048 – 1056. doi: 10.1016/S1470-2045(10)70230-8 [20] World Health Organization. Global strategy to accelerate the elimi-nation of cervical cancer as a public health problem[EB/OL]. (2020 – 11 – 17)[2022 – 10 – 15]. https://www.who.int/publications/i/item/9789240014107. [21] Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bulletin of the World Health Organiza-tion, 2019, 97(3): 230 – 238. doi: 10.2471/BLT.18.219469 [22] 疾病预防控制局. 关于印发中国病毒性肝炎防治规划(2017 —– 2020年)的通知[EB/OL]. (2017 – 11 – 10)[2022 – 10 – 17]. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml. [23] Weinbaum CM, Mast EE, Ward JW. Recommendations for identifica-tion and public health management of persons with chronic hepatitis B virus infection[J]. Hepatology, 2009, 49(S5): S35 – S44. doi: 10.1002/hep.22882 [24] Lefevre ML. Screening for hepatitis B virus infection in non-pregnant adolescents and adults: U. S. Preventive Services Task Force recommendation statement[J]. Annals of Internal Medicine, 2014, 161(1): 58 – 66. doi: 10.7326/M14-1018 [25] Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, preven-tion, diagnosis, and treatment[J]. American Family Physician, 2019, 99(5): 314 – 323. [26] 胡尚英, 赵雪莲, 张勇, 等. 《预防宫颈癌: WHO宫颈癌前病变筛查和治疗指南(第二版)》解读[J]. 中华医学杂志, 2021, 101(34): 2653 – 2657. [27] Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society[J]. CA:A Cancer Journal for Clinicians, 2020, 70(5): 321 – 346. doi: 10.3322/caac.21628 [28] 赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南 (2021, 北京)[J]. 中华肿瘤杂志, 2021, 43(4): 357 – 382. [29] 中国抗癌协会乳腺癌专业委员会. 中国乳腺癌筛查与早期诊断指南[J]. 中国癌症杂志, 2022, 32(4): 363 – 372. [30] Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?[J]. Blood, 2020, 135(4): 252 – 260. doi: 10.1182/blood.2019000813 [31] Behjati S, Gilbertson RJ, Pfister SM. Maturation block in child-hood cancer[J]. Cancer Discovery, 2021, 11(3): 542 – 544. doi: 10.1158/2159-8290.CD-20-0926 [32] Veeraraghavan S, Ramalingam SS, Khuri FR. Early detection of lung cancer in China: the immediate imperative[J]. Cancer, 2015, 121(S17): 3055 – 3057. doi: 10.1002/cncr.29601 [33] Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening[J]. New England Journal of Medicine, 2013, 368(8): 728 – 736. doi: 10.1056/NEJMoa1211776 -
点击查看大图
表(3)
计量
- 文章访问数: 34
- HTML全文浏览量: 9
- PDF下载量: 2
- 被引次数: 0